NVCT

Business Context and Reporting Period

Nuvectis Pharma, Inc. (NVCT) is a clinical-stage biopharmaceutical company focused on developing precision medicines for oncology. The filing is an Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company is classified as an emerging growth company and a smaller reporting company. Its primary asset is the product candidate NXP900, a targeted therapy inhibiting SRC and YES1 kinases, which is currently in Phase 1b clinical trials. The company ceased development of its second candidate, NXP800, in July 2025 following Phase 1b data readouts.

Key Financial Metrics

Note: The company has no debt and no long-term leases as of December 31, 2025.

Material Changes vs. Prior Period

• Increased Operating Loss: The net loss increased by approximately $7.4 million year-over-year, driven primarily by higher R&D and G&A expenses.
• R&D Expense Growth: R&D expenses rose by $5.3 million (41% increase). Key drivers included a $2.4 million increase in license milestone fees (related to NXP900), higher clinical trial expenses ($5.5 million vs. $4.3 million), and increased employee compensation.
• G&A Expense Growth: G&A expenses increased by $2.5 million (36% increase), largely due to higher professional and consulting services ($5.3 million vs. $3.5 million) and increased stock-based compensation.
• Capital Raising: In 2025, the company raised approximately $29.1 million in net proceeds through a public offering ($13.9 million net) and At-the-Market (ATM) offerings ($15.2 million net), compared to $11.7 million in 2024.
• Portfolio Change: The company discontinued the clinical development of NXP800 in July 2025, shifting focus entirely to NXP900.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes cash and cash equivalents of $31.6 million are sufficient to fund operations for at least the next 12 months. However, the company expects to require substantial additional capital to complete clinical trials and achieve commercialization.
• Clinical Progress: NXP900 Phase 1a was completed in July 2025 with no dose-limiting toxicity observed up to 300 mg/day. Phase 1b expansion studies (single agent and combination with EGFR/ALK inhibitors) are ongoing. A drug-drug interaction study was completed in July 2025.
• Key Risks:
  • Capital Requirements: Continued losses and the need for future financing may lead to dilution or forced delays in development.
  • Clinical Uncertainty: No products are approved; success depends on NXP900 demonstrating safety and efficacy in later-stage trials.
  • Regulatory and IP: Risks include denial of regulatory approval, patent challenges, and reliance on third-party manufacturers.
  • Market Volatility: The stock price is volatile, and an active trading market may not be sustained.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $31.6 million cash balance against the projected burn rate for NXP900 Phase 1b and potential Phase 2 trials.
• NXP900 Clinical Data: Review the specific safety and pharmacodynamic data from the Phase 1a completion and the design of the ongoing Phase 1b expansion.
• License Obligations: Confirm the remaining contingent milestone payments owed to the University of Edinburgh (up to $45.5 million pre-approval and $279.5 million commercial) and the impact of future fundraising on the 2.5% royalty obligation.
• Discontinued Program: Assess the financial and strategic implications of ceasing NXP800 development and the potential for any remaining obligations to the CRT Pioneer Fund.
• Stock-Based Compensation: Monitor the impact of significant stock-based compensation ($6.0 million in 2025) on future dilution and expense recognition.